Main info

Identifier:

HO36 MM

Sponsor:

HOVON

Included patients:

72

Active sites:

46

(of 46)

Title:

A study of the efficacy, morbidity and quality of life of the standard treatment with Melphalan and Prednison versus an intensified treatment in elderly patients with Multiple Myeloma: A Phase III study.

Timeline

Flow

Details

Phase:

Select:

Monitoring Type:

Objectives:

Eligibility

Inclusion Criteria:

• Patients with multiple myeloma not yet treated with chemotherapy.
• Age > 64
• WHO performance status 0, 1, 2 or 3.
• Salmon and Durie stages Ib, IIa, IIb, IIIa and IIIb.
• A well-measurable tumor parameter.

Exclusion Criteria:

• Severe cardiac, pulmonary or hepatic disease.
• Dependency on kidney function replacement therapy.
• Previously treated with cytostatics and/or alpha-interferon.
• A history of second primary malignant disease other than stage I carcinoma of the cervix and non-melanomatic cancer of the skin.

Participating Sites

= Active hospitals

= Inactive hospitals